Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD
Completed
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
Phase 2
2006-05-01
The purpose of this study is to compare the effectiveness and safety of atomoxetine in the
treatment of adolescents with coexisting alcohol or substance use disorders and Attention
Deficit Hyperactivity Disorder (ADHD).
Atomoxetine to Treat Adolescents With Coexisting Alcohol and Other Substance Use Disorder and ADHD
Completed
University of Pittsburgh
Phase 2
2006-05-01
The purpose of this study is to compare the effectiveness and safety of atomoxetine in the
treatment of adolescents with coexisting alcohol or substance use disorders and Attention
Deficit Hyperactivity Disorder (ADHD).
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
Completed
National Institute on Drug Abuse (NIDA)
Phase 2
2005-10-01
Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment
for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in
treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess
whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will
determine whether atomoxetine improves treatment retention and progress in adolescents with
ADHD and marijuana dependence.
Atomoxetine for Treating Marijuana-Abusing Adolescents Who Have Attention Deficit Hyperactivity Disorder
Completed
New York State Psychiatric Institute
Phase 2
2005-10-01
Attention Deficit Hyperactivity Disorder (ADHD) is common among adolescents seeking treatment
for marijuana dependence. The purpose of this study is to determine the use of atomoxetine in
treating adolescents who abuse marijuana and have ADHD. In addition, this study will assess
whether atomoxetine reduces ADHD symptoms as compared to a placebo. Finally, the study will
determine whether atomoxetine improves treatment retention and progress in adolescents with
ADHD and marijuana dependence.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
